The Scripps Research Institute

Taurus Biosciences, LLC

Fabrus, Inc.

The Texas A&m University System

International Aids Vaccine Initiative

Vaughn V Smider

Peter G Schultz

Omar A Bazirgan

Helen Hongyuan Mao

Meng-Lin Tsao

Hongyuan Helen Mao

Tyson Chase

Yong Zhang

Chang Liu

James Graziano

Byeong Doo Song

Richard A Lerner

Dennis R Burton

Feng Wang

Ian A Wilson

Jan Grunewald

Waithaka Mwangi

Devin Sok

Roshan Perera

Michael Criscitiello

Cornelia Bentley

The present disclosure relates to methods for generating broadly neutralizing bovine anti-HIV Env antibodies, compositions comprising the broadly neutralizing bovine antibodies, and methods of treatment or prevention of HIV using the broadly neutralizing bovine antibodies. In certain embodiments, a broadly neutralizing bovine antibody comprises a polyclonal F(ab) or F(ab')2 fragment. In certain embodiments, a broadly neutralizing bovine antibody comprises a humanized bovine monoclonal antibody.

Rapid elicitation of broadly neutralizing antibodies to HIV Env

Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.

Ultralong complementarity determining regions and uses thereof

Methods for making a combinatorial antibody library from human germline segments are provided. Also provided are libraries of nucleic acid molecules compiled from germline segments encoding VL chains and libraries of nucleic acid molecules encoding VH chains, and resulting antibody libraries. The libraries are provided as addressable libraries. Methods for screening antibody libraries against a target protein antigen, and the identified or selected antibodies are provided.

Combinatorial antibody libraries and uses thereof

The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.

Humanized antibodies

Provided herein is a rational method of affinity maturation to evolve the activity of an antibody or portion thereof based on the structure/affinity or activity relationship of an antibody. The resulting affinity matured antibodies exhibit improved or optimized binding affinity for a target antigen.

Methods for affinity maturation-based antibody optimization

Provided herein are anti-DLL4 antibodies and methods of using anti-DLL4 antibodies as therapeutic agents in diseases or disorders associated with DLL4.

Anti-DLL4 antibodies and uses thereof

The invention provides methods and compositions for screening polypeptide libraries that include variants comprising unnatural amino acids. In addition, the invention provides vector packaging systems and methods for packaging a nucleic acid in a vector. Compositions of vectors produced by the methods and systems are also provided.

Directed evolution using proteins comprising unnatural amino acids

The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.

Breaking immunological tolerance with a genetically encoded unnatural amino acid

Growing community of inventors

La Jolla, CA, United States of America

Vaughn V Smider